Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

InxMed Will Begin China Trial of FAPα Inhibitor to Lower Immunotherapy Resistance

publication date: Aug 30, 2023

Nanjing InxMed reported OMTX705, a first-in-class ADC targeting fibroblast-activating protein α (FAPα), was approved to start China trials. FAP is a type-II transmembrane serine protease expressed almost exclusively in pathological conditions including cancer, where it is expressed in cancer-associated fibroblasts (CAF) surrounding the tumor cells and microvasculature. InxMed, which focuses on resistance to oncology drugs, said FAP-expressing CAFs have been shown to play important roles in tumor drug resistance. The company in-licensed Asian commercial rights to OMTX705 from Spain’s Oncomatryx, a company developing novel drugs that target the tumor microenvironment. More details....

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital